July 1st, 2017
View Archives Issues
Once a drug receives accelerated approved, manufacturers are free to charge whatever they believe the market will bear without evidence that the drug affects disease progression.
Nationwide epidemic has raised questions regarding the long-term use of such medication for chronic pain conditions.
The suit alleges fraudulent marketing that misled the state, prescribers, and patients about the risks of these medications.
In this section: FDA approves new amyotrophic lateral sclerosis, expands the indication for pembrolizumab, adds giant cell arteritis to the indication for tocilizumab, and green lights generic ADHD drug.